T. Rowe Price Associates’s Abeona Therapeutics ABEO Stock Holding History

T. Rowe Price Associates’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139K	Buy	31,005 +6,878	+29%	+$34.4K	﹤0.01%	2935
2025 Q4	$128K	Buy	24,127 +969	+4%	+$4.88K	﹤0.01%	2913
2025 Q3	$123K	Buy	23,158 +1,249	+6%	+$7.92K	﹤0.01%	2890
2025 Q2	$125K	Buy	+21,909	New	+$125K	﹤0.01%	2849
2021 Q4	–	Sell	-976	Closed	-$27K	–	2974
2021 Q3	$27K	Buy	+976	New	+$31.3K	﹤0.01%	2924
2019 Q2	–	Sell	-100,134	Closed	-$18.4M	–	2542
2019 Q1	$18.4M	Sell	100,134 -1,848	-2%	-$330K	﹤0.01%	1198
2018 Q4	$18.2M	Sell	101,982 -39,239	-28%	-$8.56M	﹤0.01%	1172
2018 Q3	$45.2M	Sell	141,221 -8,763	-6%	-$3.11M	0.01%	951
2018 Q2	$60M	Buy	149,984 +96,537	+181%	+$42.2M	0.01%	823
2018 Q1	$19.2M	Buy	53,447 +24,077	+82%	+$8.95M	﹤0.01%	1200
2017 Q4	$11.6M	Buy	29,370 +21,011	+251%	+$8.69M	﹤0.01%	1312
2017 Q3	$3.56M	Buy	+8,359	New	+$2.25M	﹤0.01%	1479

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates's ABEO Position: Q1 2026 in Review

T. Rowe Price Associates increased its Abeona Therapeutics (ABEO) stake by 29% in Q1 2026, buying an estimated $34.4K and bringing the position to 31,005 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2935.

T. Rowe Price Associates first reported a position in ABEO in Q3 2017 and has held it in 12 quarters since. The position peaked at $60M in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

T. Rowe Price Associates held 31,005 shares of Abeona Therapeutics worth $139K as of Q1 2026.
T. Rowe Price Associates bought 6,878 Abeona Therapeutics shares in Q1 2026, an estimated $34.4K.
Abeona Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2935 holding.
T. Rowe Price Associates first reported a position in Abeona Therapeutics in Q3 2017 and has held it in 12 quarters since.
T. Rowe Price Associates's Abeona Therapeutics position peaked at $60M in Q2 2018.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.